Free Trial

Fate Therapeutics (FATE) Competitors

Fate Therapeutics logo
$1.16 +0.01 (+0.87%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$1.16 0.00 (-0.09%)
As of 04:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FATE vs. SEPN, SIGA, ATYR, PGEN, MREO, CAPR, KMDA, RAPP, CGEM, and PRTC

Should you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Septerna (SEPN), Siga Technologies (SIGA), aTyr Pharma (ATYR), Precigen (PGEN), Mereo BioPharma Group (MREO), Capricor Therapeutics (CAPR), Kamada (KMDA), Rapport Therapeutics (RAPP), Cullinan Therapeutics (CGEM), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry.

Fate Therapeutics vs. Its Competitors

Fate Therapeutics (NASDAQ:FATE) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

97.5% of Fate Therapeutics shares are held by institutional investors. 5.5% of Fate Therapeutics shares are held by insiders. Comparatively, 4.3% of Septerna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Septerna has lower revenue, but higher earnings than Fate Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fate Therapeutics$13.63M9.75-$186.26M-$1.49-0.78
Septerna$1.08M481.91-$71.80MN/AN/A

Fate Therapeutics currently has a consensus target price of $3.83, suggesting a potential upside of 230.46%. Septerna has a consensus target price of $26.75, suggesting a potential upside of 129.02%. Given Fate Therapeutics' higher possible upside, equities analysts plainly believe Fate Therapeutics is more favorable than Septerna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fate Therapeutics
0 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.13
Septerna
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

In the previous week, Fate Therapeutics had 4 more articles in the media than Septerna. MarketBeat recorded 7 mentions for Fate Therapeutics and 3 mentions for Septerna. Fate Therapeutics' average media sentiment score of 0.72 beat Septerna's score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fate Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Septerna
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Septerna has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,318.93%. Septerna's return on equity of 0.00% beat Fate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Fate Therapeutics-1,318.93% -47.17% -34.60%
Septerna N/A N/A N/A

Summary

Septerna beats Fate Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Fate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FATE vs. The Competition

MetricFate TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$131.79M$2.96B$5.55B$9.04B
Dividend YieldN/A2.43%5.25%4.04%
P/E Ratio-0.7821.1127.2020.14
Price / Sales9.75251.53413.3398.20
Price / CashN/A42.7337.5058.41
Price / Book0.417.748.085.60
Net Income-$186.26M-$54.96M$3.16B$248.43M
7 Day Performance1.31%9.10%4.68%5.47%
1 Month Performance-25.16%5.73%4.49%7.87%
1 Year Performance-65.88%2.79%30.99%18.75%

Fate Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FATE
Fate Therapeutics
4.288 of 5 stars
$1.16
+0.9%
$3.83
+230.5%
-62.8%$131.79M$13.63M-0.78550
SEPN
Septerna
1.1799 of 5 stars
$10.85
-4.6%
$26.75
+146.5%
N/A$483.45M$977K0.00N/A
SIGA
Siga Technologies
1.5149 of 5 stars
$6.73
+0.6%
N/A-19.1%$480.80M$120.33M10.0440News Coverage
Options Volume
ATYR
aTyr Pharma
2.5008 of 5 stars
$5.30
-0.2%
$20.20
+281.1%
N/A$471.72MN/A-6.5453Gap Down
High Trading Volume
PGEN
Precigen
4.2871 of 5 stars
$1.59
-1.9%
$6.00
+277.4%
+24.0%$469.34M$3.92M-2.84190
MREO
Mereo BioPharma Group
2.2613 of 5 stars
$2.92
+1.7%
$7.60
+160.3%
-55.2%$464.28M$10M-41.7140News Coverage
Analyst Forecast
Gap Down
High Trading Volume
CAPR
Capricor Therapeutics
3.4346 of 5 stars
$9.90
-3.4%
$32.22
+225.5%
+147.8%$452.23M$22.27M-6.97101
KMDA
Kamada
3.7092 of 5 stars
$7.71
-2.2%
$13.00
+68.6%
+35.9%$443.40M$160.95M26.59360
RAPP
Rapport Therapeutics
1.9585 of 5 stars
$12.04
flat
$28.00
+132.6%
-35.5%$439.44MN/A-3.49N/AAnalyst Forecast
CGEM
Cullinan Therapeutics
1.9457 of 5 stars
$7.42
-5.0%
$30.00
+304.3%
-51.1%$437.89MN/A-2.5530News Coverage
PRTC
PureTech Health
2.0811 of 5 stars
$18.01
flat
$45.00
+149.9%
-26.8%$432.60M$4.83M0.00100News Coverage
Gap Down

Related Companies and Tools


This page (NASDAQ:FATE) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners